The FDA granted accelerated approval to nivolumab (Opdivo, Bristol-Myers Squibb) for the treatment of patients with metastatic small cell lung cancer (SCLC) whose disease progresses after platinum-based chemotherapy and at least one other line of therapy.
“While immuno-oncology innovations have dramatically changed how oncologists approach certain cancers, we have had limited progress for patients with small cell lung cancer,” noted Leora Horn, MD, MSc, the director of the Thoracic